Glipgludin Contraindications

Sitagliptin Phosphate + Metformin Hydrochloride HCl (Glipgludin) is contraindicated in patients with: Severe renal impairment (eGFR <30 mL/min/1.73 m²) (see Metformin Hydrochloride: Renal Impairment under Precautions).
Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of Sitagliptin Phosphate + Metformin Hydrochloride HCl (Glipgludin) (see Sitagliptin Phosphate: Hypersensitivity Reactions under Precautions and Post-Marketing Experience under Adverse Reactions).
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
Sitagliptin Phosphate + Metformin Hydrochloride HCl (Glipgludin) should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see Metformin Hydrochloride under Precautions).